1. Home
  2. NX vs AKBA Comparison

NX vs AKBA Comparison

Compare NX & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NX
  • AKBA
  • Stock Information
  • Founded
  • NX 1927
  • AKBA 2007
  • Country
  • NX United States
  • AKBA United States
  • Employees
  • NX N/A
  • AKBA N/A
  • Industry
  • NX Metal Fabrications
  • AKBA Biotechnology: Pharmaceutical Preparations
  • Sector
  • NX Industrials
  • AKBA Health Care
  • Exchange
  • NX Nasdaq
  • AKBA Nasdaq
  • Market Cap
  • NX 824.7M
  • AKBA 958.6M
  • IPO Year
  • NX N/A
  • AKBA 2014
  • Fundamental
  • Price
  • NX $18.55
  • AKBA $3.68
  • Analyst Decision
  • NX Strong Buy
  • AKBA Strong Buy
  • Analyst Count
  • NX 1
  • AKBA 5
  • Target Price
  • NX $38.00
  • AKBA $6.90
  • AVG Volume (30 Days)
  • NX 533.3K
  • AKBA 6.6M
  • Earning Date
  • NX 06-05-2025
  • AKBA 08-07-2025
  • Dividend Yield
  • NX 1.73%
  • AKBA N/A
  • EPS Growth
  • NX N/A
  • AKBA N/A
  • EPS
  • NX 0.39
  • AKBA N/A
  • Revenue
  • NX $1,625,028,000.00
  • AKBA $184,909,000.00
  • Revenue This Year
  • NX $49.00
  • AKBA $26.88
  • Revenue Next Year
  • NX $2.99
  • AKBA $44.34
  • P/E Ratio
  • NX $47.21
  • AKBA N/A
  • Revenue Growth
  • NX 47.66
  • AKBA N/A
  • 52 Week Low
  • NX $15.30
  • AKBA $0.80
  • 52 Week High
  • NX $34.97
  • AKBA $4.08
  • Technical
  • Relative Strength Index (RSI)
  • NX 51.50
  • AKBA 63.81
  • Support Level
  • NX $17.81
  • AKBA $3.48
  • Resistance Level
  • NX $19.07
  • AKBA $3.87
  • Average True Range (ATR)
  • NX 0.88
  • AKBA 0.24
  • MACD
  • NX -0.05
  • AKBA -0.04
  • Stochastic Oscillator
  • NX 34.76
  • AKBA 35.71

About NX Quanex Building Products Corporation

Quanex Building Products Corp is a manufacturer of components sold to original equipment manufacturers in the building products industry. It manufactures engineered products like window and door components that include flexible insulating glass spacers, extruded vinyl profiles, window and door screens, solar panel sealants and precision-formed metal and wood products among others. Its three operating segments are North American Fenestration being the key revenue driver, European Fenestration, and North American Cabinet Components. Geographically, it derives a majority of revenue from the United States.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.

Share on Social Networks: